Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

Succinate Receptor Antibodies

Close filters
No results were found for the filter!
NEW
 Immunohistochemical identification of SUCNR1 Receptor in Pancreas
SUCNR1/GPR91 (IHC-grade), Succinate Receptor...
The SUCNR1 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human SUCNR1. It can be used to detect total SUCNR1 receptors in Western blots independent of phosphorylation. The SUCNR1 antibody can also...
375.00 € *
NEW
Validation of the SUCNR1 Receptor in transfected HEK293 cells
SUCNR1/GPR91 (non-phospho), Succinate Receptor...
The non-phospho-SUCNR1 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human SUCNR1. It can be used to detect total SUCNR1 receptors in Western blots independent of phosphorylation. The SUCNR1...
375.00 € *

SUCNR1 (also known as GPR91) is a metabolite-sensing G protein-coupled receptor that is activated by succinate, a key intermediate of the citric acid cycle. Upon activation, SUCNR1 primarily signals through Gi and Gq proteins, influencing various physiological processes including inflammation, metabolism, and blood pressure regulation. SUCNR1 is expressed in a range of tissues, including the kidneys, liver, retina, heart, adipose tissue, and immune cells such as macrophages and dendritic cells. Its expression is often upregulated under stressful metabolic conditions, such as hypoxia, hyperglycemia, and inflammation. SUCNR1 is considered a promising pharmacological target due to its role in diseases associated with metabolic dysfunction, hypertension, diabetic complications, retinal diseases, and inflammatory responses. Targeting SUCNR1 may offer therapeutic potential in diabetic nephropathy, age-related macular degeneration, cardiovascular diseases, and obesity-related inflammation. For more information on SCNR1 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F16/2023.1.

 

SUCNR1 (also known as GPR91) is a metabolite-sensing G protein-coupled receptor that is activated by succinate, a key intermediate of the citric acid cycle. Upon activation, SUCNR1 primarily... read more »
Close window
Succinate Receptor Antibodies

SUCNR1 (also known as GPR91) is a metabolite-sensing G protein-coupled receptor that is activated by succinate, a key intermediate of the citric acid cycle. Upon activation, SUCNR1 primarily signals through Gi and Gq proteins, influencing various physiological processes including inflammation, metabolism, and blood pressure regulation. SUCNR1 is expressed in a range of tissues, including the kidneys, liver, retina, heart, adipose tissue, and immune cells such as macrophages and dendritic cells. Its expression is often upregulated under stressful metabolic conditions, such as hypoxia, hyperglycemia, and inflammation. SUCNR1 is considered a promising pharmacological target due to its role in diseases associated with metabolic dysfunction, hypertension, diabetic complications, retinal diseases, and inflammatory responses. Targeting SUCNR1 may offer therapeutic potential in diabetic nephropathy, age-related macular degeneration, cardiovascular diseases, and obesity-related inflammation. For more information on SCNR1 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F16/2023.1.

 

Recently viewed